194 related articles for article (PubMed ID: 15046183)
1. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?
Bugianesi E; Zannoni C; Vanni E; Marzocchi R; Marchesini G
Dig Liver Dis; 2004 Mar; 36(3):165-73. PubMed ID: 15046183
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
Schäffler A; Schölmerich J; Büchler C
Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance.
Roden M
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311
[TBL] [Abstract][Full Text] [Related]
5. The role of cytokines in non-alcoholic fatty liver disease.
Tilg H
Dig Dis; 2010; 28(1):179-85. PubMed ID: 20460908
[TBL] [Abstract][Full Text] [Related]
6. Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin HZ; Yang SQ; Chuckaree C; Kuhajda F; Ronnet G; Diehl AM
Nat Med; 2000 Sep; 6(9):998-1003. PubMed ID: 10973319
[TBL] [Abstract][Full Text] [Related]
7. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
[TBL] [Abstract][Full Text] [Related]
9. Review article: hepatic steatosis and insulin resistance.
Lonardo A; Lombardini S; Ricchi M; Scaglioni F; Loria P
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():64-70. PubMed ID: 16225477
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
11. [Insulin resistance in non-alcoholic fatty liver disease].
Park JH
Korean J Hepatol; 2006 Mar; 12(1):16-30. PubMed ID: 16565603
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease pathogenesis: the present and the future.
Petta S; Muratore C; Craxì A
Dig Liver Dis; 2009 Sep; 41(9):615-25. PubMed ID: 19223251
[TBL] [Abstract][Full Text] [Related]
13. Review article: Drug therapy for non-alcoholic fatty liver disease.
Comar KM; Sterling RK
Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
[TBL] [Abstract][Full Text] [Related]
14. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance.
Baranova A; Gowder SJ; Schlauch K; Elariny H; Collantes R; Afendy A; Ong JP; Goodman Z; Chandhoke V; Younossi ZM
Obes Surg; 2006 Sep; 16(9):1118-25. PubMed ID: 16989692
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
Ratziu V; Caldwell S; Neuschwander-Tetri BA
Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
[TBL] [Abstract][Full Text] [Related]
16. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
Moore GB; Pickavance LC; Briscoe CP; Clapham JC; Buckingham RE; Wilding JP
Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.
Bugianesi E; Marzocchi R; Villanova N; Marchesini G
Best Pract Res Clin Gastroenterol; 2004 Dec; 18(6):1105-16. PubMed ID: 15561641
[TBL] [Abstract][Full Text] [Related]
18. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic steatohepatitis and metabolic syndrome.
Machado M; Cortez-Pinto H
Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):637-42. PubMed ID: 16912563
[TBL] [Abstract][Full Text] [Related]
20. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
